Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Tuesday,Briefing.com Automated Import reports. They presently have a $10.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 423.56% from the company’s previous close.
Other analysts have also recently issued research reports about the company. StockNews.com cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Barclays lifted their target price on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th.
View Our Latest Analysis on Sangamo Therapeutics
Sangamo Therapeutics Price Performance
Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. The business had revenue of $49.41 million for the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. During the same period last year, the firm posted ($0.34) earnings per share. As a group, analysts expect that Sangamo Therapeutics will post -0.46 EPS for the current year.
Institutional Trading of Sangamo Therapeutics
A number of large investors have recently bought and sold shares of the business. Meritage Portfolio Management boosted its stake in shares of Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 6,740 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Sangamo Therapeutics by 55.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 38,850 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Sangamo Therapeutics by 5.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock valued at $956,000 after buying an additional 57,125 shares during the last quarter. XTX Topco Ltd raised its stake in Sangamo Therapeutics by 167.8% in the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 64,981 shares during the period. Finally, Golden State Equity Partners raised its position in shares of Sangamo Therapeutics by 35.2% in the third quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 69,368 shares during the period. 56.93% of the stock is owned by institutional investors.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
Read More
- Five stocks we like better than Sangamo Therapeutics
- How to Invest in the Best Canadian Stocks
- Amazon’s Healthcare Gamble: A New Era of Medical Disruption
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Semiconductor Giant Synopsys Slides 14% — Time to Take Notice
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Tesla’s Closes in on $400: From Laggard to Leader in 2024
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.